Clinical Research

Evaluation of New Imaging Techniques for Localised Prostate Cancer Patients

Evaluation of Multiparametric Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) with a [68Ga]gallium-labelled prostate-specific membrane antigen (PSMA) ligand for the Detection of Multiple Cancer Foci in Localized Prostate Cancer Patients.

The purpose of this study is to investigate whether two imaging procedures can improve the identification of cancer tissues in patients with localized prostate cancer. The two procedures are:

Multi Parameteric Magnetic Resonance Imaging (MP MRI)
This type of scan does not use radiation. As in standard MRI, MP MRI uses magnetic signal to build up a picture of your prostate. However, in addition to this, MP MRI uses additional types of magnetic signals to build up more complete images of the prostate. This gives an overall assessment of your prostate. It is believed the MP MRI approach increases the accuracy of the scan result but we cannot be sure of this without doing this study.

Positron Emission Tomography (PET)
PET scans are often used in the management of cancer and for diagnosis of suspected cancer conditions. This type of scan involves the use of a PET scanner and a radiotracer (radioactive agent). The PET radiotracer used in this study is Gallium-labelled Prostate-Specific Membrane Antigen (PSMA) ligand which is a radioactive protein marker.

Study Population

Prostate cancer participants with biopsy proven carcinoma who are planned for prostatectomy.

Further Information and Who to Contact

Should you want any further information concerning this project, or if you have any medical problems which may be related to your involvement in the project (for example, any side effects), you can contact:

the principal study doctor
Dr Peter Heathcote
phone: +61 7 38303310
email: pheathcote@brisbaneurologyclinic.com.au

the study doctor and investigator
Dr Handoo Rhee
phone: +61 7 3176 7957
email: handoorhee@gmail.com

the clinical coordinator
Dr Maggie Fung
phone: +61 7 31767449

Further information is also available from https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366366